PATENT CLAIM ANALYSIS

Application Number: 15886978
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["424", "497000"]

Abstract:
Disclosed herein are compositions and methods for preventing or treating acute or chronic oral mucositis, esophagitis, enteritis, colitis, or gastrointestinal acute radiation syndrome (GI-ARS) caused by radiation exposure, using one or more enteron sorbent polymers administered gastrointestinally (e.g. orally, via feeding or gastric tube, via ostomy, or rectally).

Claim (Index 22):
A composition for preventing or treating acute or chronic oral mucositis, esophagitis, enteritis, colitis, or gastrointestinal acute radiation syndrome (GI-ARS) caused by radiation exposure, the composition comprising one or more enteron sorbent polymers;\n a) wherein the enteron sorbent polymers comprise a biocompatible porous polymer sorbent; or b) wherein the enteron sorbent polymers comprise any particle size range as disclosed herein; or; c) wherein the enteron sorbent polymers are capable of serving as a radioprotector (preventative therapy) for acute and/or delayed/chronic radiation enteritis and radiation syndrome; or d) wherein the enteron sorbent polymer are capable of serving as a radio-mitigator (active treatment) post radiation exposure for either acute or delayed/chronic radiation enteritis or radiation syndrome; or e) wherein the enteron sorbent polymers have a positive effect on radiation mediated lung syndrome; or f) wherein the enteron sorbent polymers have a positive effect on radiation mediated heme syndrome; or g) wherein the enteron sorbent polymers are used for the prevention and treatment complications of cosmic or space radiation; or h) wherein the enteron sorbent polymers are used for the prevention and treatment of complications of radiation cancer therapy; or i) wherein the enteron sorbent polymers as a concurrent therapy are capable of facilitating, sustaining and/or increasing the doses of radiation therapy for effective cancer treatment; or j) wherein the enteron sorbent polymers are used for the prevention and treatment of complications of radiological catastrophe due to dirty bomb explosion, accidental nuclear power plant malfunction, and an act of terrorism; or k) wherein the enteron sorbent polymers improve survival outcome; l) wherein the enteron sorbent polymers help retain weight; or m) wherein the enteron sorbent polymers help reduce intestinal inflammation, gut permeability, protect or treat gut epithelium, prevent bacterial, endotoxin and toxin translocation, the systemic inflammatory response syndrome (SIRS) and septicemia; or n) wherein the enteron sorbent polymers provide symptomatic improvement in the severity and duration of diarrhea, vomiting and abdominal pain; or o) wherein said enteron sorbent polymer comprises cross-linked polymeric material derived from the reaction of a cross-linker with one or more of the following polymerizable monomers: styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, and methyl acrylate; or p) wherein the solid form of the enteron sorbent polymer is characterized as having a pore structure having a total volume of pore sizes in the range of from 10 \u212b to 250,000 \u212b greater than 0.3 cc/g to 3.0 cc/g dry polymer; wherein the ratio of pore volume between 10 \u212b to 250,000 \u212b in diameter to pore volume between 250 \u212b to 250,000 \u212b in diameter of the cross-linked polymeric material is smaller than 7:1 and wherein the ratio of pore volume between 10 \u212b to 250,000 \u212b in diameter to pore volume between 50 \u212b to 250,000 \u212b in diameter of the cross-linked polymeric material is less than 2:1; or q) wherein the enteron sorbent polymers adsorb inflammatory mediators and toxins, wherein said inflammatory mediators and stimulators comprise cytokines, superantigens, monokines, chemokines, interferons, free radicals, proteases, arachidonic acid metabolites, prostacyclins, beta endorphins, anandimide, 2-arachadonylglycerol, tetrahydrobiopterin, serotonin, histamine, bradykinin, soluble CD40 ligand, bioactive lipids, oxidized lipids, cell-free hemoglobin, growth factors, glycoproteins, prions, toxins, bacterial and viral toxins, endotoxins, drugs, vasoactive substances, foreign antigens, and antibodies; or r) wherein the enteron sorbent polymer is in a form capable of being administered via oral, feeding tube, gastric tube, via ostomy, or rectal routes; or s) wherein the enteron sorbent polymer is in capsule, tablet, salve, poultice, enema, suppository, or slurry form; or t) any combination of two or more of a) through s);\n wherein said enteron sorbent polymer is characterized as having a pore structure having a total volume of pore sizes in the range of from 10 \u212b to 250,000 \u212b greater than 0.3 cc/g to 3.0 cc/g dry polymer; wherein the ratio of pore volume between 10 \u212b to 250,000 \u212b in diameter to pore volume between 250 \u212b to 250,000 \u212b in diameter of the cross-linked polymeric material is smaller than 7:1 and wherein the ratio of pore volume between 10 \u212b to 250,000 \u212b in diameter to pore volume between 50 \u212b to 250,000 \u212b in diameter of the cross-linked polymeric material is less than 2:1.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 88.0
- Lexical Diversity: 1.40909
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15515328', '13344166', '13637775', '15635517', '14238548']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7031415325887967
- 35 USC 102 Novelty (BERT): 0.6628665448334582
- Combined Prediction Score: 0.6991140338132629
- Mean Citation Score: 398.771398
- Max Citation Score: 794.7503
- Similarity Product: 590.0811655367793

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test